Active surveillance cultures and contact precautions for control of multidrug-resistant organisms: Ethical considerations

Clinical Infectious Diseases

Volumn 47, Issue 1, 2008, Pages 110-116

  Santos, Roberto P ^a   Mayo, Thomas W ^b   Siegel, Jane D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b SMU Dedman School of Law   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; LIPOPEPTIDE; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; CLINICAL RESEARCH; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; INFECTION CONTROL; MEDICAL CARE; MEDICAL DECISION MAKING; MEDICAL ETHICS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PATIENT CARE; PATIENT RIGHT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK FACTOR; TOTAL QUALITY MANAGEMENT; BACTERIAL INFECTION; BACTERIUM; CROSS INFECTION; DISEASE TRANSMISSION; DRUG EFFECT; HEALTH SURVEY; METHODOLOGY; MICROBIOLOGY; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HEALTH FACILITIES; HUMANS; INFECTION CONTROL; METHICILLIN RESISTANCE; PRACTICE GUIDELINES AS TOPIC; SENTINEL SURVEILLANCE; STAPHYLOCOCCUS AUREUS;

EID: 46249113559     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/588789     Document Type: Review

References (50)

1. Gordon J. Medical humanities: to cure sometimes, to relieve often, to comfort always. Med J Aust 2005; 182:5-8.
2. Bulger RE. Research with human beings. In: Bulger RE, Heitman E, Reiser SJ, eds. The ethical dimensions of the biological and health sciences. 2nd ed. New York: Cambridge University Press, 2002:117-25.
3. APIC. Centers for Medicare and Medicaid Services conditions of participation (CoPs) revised interpretive guidelines. Washington, DC: Association for Professionals in Infection Control and Epidemiology, 2006. Accessed at http://www.apic.org/Content/NavigationMenu/ GovernmentAdvocacy/CMS/Interp_Guidelines_Draft60906.pdf on 3 July 2007 (now defunct).
4. Bryan CS, Call TJ, Elliott KC. The ethics of infection control: philosophical frameworks. Infect Control Hosp Epidemiol 2007; 28:1077-84.
5. McDonald LC. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin Infect Dis 2006; 42(Suppl 2):S65-71.
6. Siegel JD, Rhinehart E, Jackson M, Chiarello L. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007; 35(Suppl 2):S165-93.
7. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-77.
8. Collins C, Drew R, Cormican M. Ethical considerations regarding the administration of oseltamivir for infection control indications. Clin Infect Dis 2007; 45:133-4.
9. Lo B, Katz MH. Clinical decision making during public health emergencies: ethical considerations. Ann Intern Med 2005; 143:493-8.
10. Wynia MK. Ethics and public health emergencies: rationing vaccines. Am J Bioeth 2006; 6:4-7.
11. Thompson AK, Faith K, Gibson JL, Upshur RE. Pandemic influenza preparedness: an ethical framework to guide decision-making. BMC Med Ethics 2006; 7:E12.
12. Lemon SM, Hamburg MA, Sparling PF, Choffnes ER, Mack A. Ethical and legal considerations in mitigating pandemic disease: workshop summary. Washington, DC: National Academies Press, 2007. Available at: http://www.nap.edu/ catalog/11917.html. Accessed 19 August 2007.
13. Selgelid MJ. Ethics and infectious disease. Bioethics 2005; 19:272-89.
14. Mayo TW. Commentary: changing professional values. Pediatr Infect Dis J 2003; 22:1096-8.
15. Rolinson GN, Geddes AM. The 50th anniversary of the discovery of 6-aminopenicillanic acid (6-APA). Int J Antimicrob Agents 2007; 29:3-8.
16. Knobler SL, Lemon SM, Najari M, Burroughs T. The resistance phenomenon in microbes and infectious disease vectors - implications for human health and strategies for containment (workshop summary). Washington, DC: National Academies Press, 2003.
17. Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997; 18:275-91.
18. Strausbaugh LJ, Siegel JD, Weinstein RA. Preventing transmission of multidrug-resistant bacteria in health care settings: a tale of 2 guidelines. Clin Infect Dis 2006; 42:828-35.
19. Institute of Medicine. Antimicrobial resistance: issues and options. In: Harrison PF, Lederberg J, eds. Forum on emerging infections. Washington, DC: National Academies Press, 1998:8-74.
20. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42(Suppl 2):S82-9.
21. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003; 24:362-86.
22. Hidron AI, Kourbatova EV, Halvosa JS, et al. Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis 2005; 41:159-66.
23. Haley CC, Mittal D, Laviolette A, Jannapureddy S, Parvez N, Haley RW. Methicillin-resistant Staphylococcus aureus infection or colonization at hospital admission: multivariable risk factor screening to increase efficiency of surveillance culturing. J Clin Microbiol 2007; 45:3031-8.
24. Institute for Healthcare Improvement. Protecting 5 million lives: campaign materials. Cambridge, MA: Institute for Healthcare Improvement, 2007. Available at: http://www.ihi.org/IHI/Programs/Campaign/Campaign. htm?TabIDp2. Accessed 7 August 2007.
25. Department of Veterans Affairs, Veterans Health Administration. VHA directive 2007-002: methicillin-resistant Staphylococcus aureus (MRSA) initiative. 2007.
26. Weber SG, Huang SS, Oriola S, et al. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the joint SHEA and APIC task force. Infect Control Hosp Epidemiol 2007; 28:249-60.
27. Diekema DJ, Edmond MB. Look before you leap: active surveillance for multidrug-resistant organisms. Clin Infect Dis 2007; 44:1101-7.
28. Herwaldt LA. Ethical aspects of infection control. Infect Control Hosp Epidemiol 1996; 17:108-13.
29. Koller DF, Nicholas DB, Goldie RS, Gearing R, Selkirk EK. Bowlby and Robertson revisited: the impact of isolation on hospitalized children during SARS. J Dev Behav Pediatr 2006; 27:134-40.
30. Catalano G, Houston SH, Catalano MC, et al. Anxiety and depression in hospitalized patients in resistant organism isolation. South Med J 2003; 96:141-5.
31. Saint S, Higgins LA, Nallamothu BK, Chenoweth C. Do physicians examine patients in contact isolation less frequently? A brief report. Am J Infect Control 2003; 31:354-6.
32. Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. JAMA 2003; 290:1899-905.
33. Andrews R, Biggs M, Seidel M, et al., eds. The Columbia world of quotations. New York: Columbia University Press, 1996. Available at: http://www.bartleby.com/66/34/28334.html. Accessed 22 August 2007.
34. Grodin MA, Annas GJ. Legacies of Nuremberg: medical ethics and human rights. JAMA 1996; 276:1682-3.
35. Katz J. The Nuremberg Code and the Nuremberg trial: a reappraisal. JAMA 1996; 276:1662-6.
36. World Medical Association. Declaration of Helsinki: ethical principles for the medical research involving human subjects. In: Bulger RE, Heitman E, Reiser SJ, ed. The ethical dimensions of the biological and health sciences. New York: Cambridge University Press, 2002:148-52.
37. Ryan KJ, Brady JV, Cooke RE, et al. The Belmont report: ethical principles and guidelines for the protection of human subjects of research. In: National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, ed. The ethical dimensions of the biological and health sciences. 2nd ed. New York: Cambridge University Press, 2002:128-38.
38. Korn D. Medical information privacy and the conduct of biomedical research. Acad Med 2000; 75:963-8.
39. National Institutes of Health. Title 45 CFR, part 46: protection of human subjects. Washington, DC: Department of Health and Human Services, 2005. Available at: http://ohsr.od.nih.gov/guidelines/45cfr46.html. Accessed 18 June 2007.
40. Lynn J, Baily MA, Bottrell M, et al. The ethics of using quality improvement methods in health care. Ann Intern Med 2007; 146:666-73.
41. Grady C. Quality improvement and ethical oversight. Ann Intern Med 2007; 146:680-1.
42. Miller FG, Emanuel EJ. Quality-improvement research and informed consent. N Engl J Med 2008; 358:765-7.
43. Curran WJ. Public health and the law: informed consent and blanket consent forms. Am J Public Health 1971; 61:1245-6.
44. Rozovsky FA. Consent to treatment: a practical guide. 4th ed. New York: Aspen Publishers, 2007.
45. Office for Human Research Protections. Federal policy for the protection of human subjects (often referred to as the "common rule"). Washington, DC: Department of Health and Human Services, 2007. Available at: http://www.hhs.gov/ohrp/policy/common.html. Accessed 20 June 2007.
46. Hakimian R, Korn D. Ownership and use of tissue specimens for research. JAMA 2004; 292:2500-5.
47. Rosenthal MB, Dudley RA. Pay-for-performance: will the latest payment trend improve care? JAMA 2007; 297:740-4.
48. Lee TH. Pay for performance, version 2.0? N Engl J Med 2007; 357:531-3.
49. Beauchamp TL, Childress JF. Justice: principles of biomedical ethics. New York: Oxford University Press, 2001:225-82.
50. Markel H. "I swear by Apollo" - on taking the Hippocratic oath. N Engl J Med 2004; 350:2026-9.